A new ivermectin trial, the first from Saudi Arabia!
It confusing, though. I don't think it's actually a trial, even though it's registered as such at ClinicalTrials. It seems to be more of a round-up of recent research.
The study will look at:
Convalescent plasma transfusion
Hydroxychloroquine
DAS181
Ivermectin
Interferon Beta-1A
Somehow it will involve 200 patients in a observational cohort restrospective study.
Start date: 2020-07-25
Primary completion: 2020-08-15
Study completion: 2020-09-20
#Brief Summary:
On 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide. There are constant efforts by Health care workers to seek information regarding the Interventional and Observational studies which can help in decision making regarding effective handling of COVID-19 infected patients. It is also important to track on the happenings in various frontiers of COVID-19 Research in view of historical interest and clinical relevance. This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research. This study aims to get a birds eye view of ongoing COVID-19 Research scenario worldwide. This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.
I never heard of DAS181. There are 5 trials looking at DAS181 vs COVID-19. It's a US drug that's been fast-tracked by the FDA.
DAS181 is a recombinant sialidase protein that cleaves sialic acid located on the surface of epithelial cells lining the human respiratory tract. Many different viruses use sialic acid as a receptor for infecting the epithelial cells, and treatment with DAS181 can therefore block virus entry and prevent viral infection and spread. The drug has demonstrated anti-viral activity against multiple sialic acid-dependent viruses, which makes it uniquely suitable as a broad-spectrum treatment for many different respiratory viral infections. DAS181 is delivered in a nebulized formulation using Aerogen® Solo aerosol drug delivery technology.
[-] TrumpLyftAlles | 1 points | Jul 08 2020 02:30:54
A new ivermectin trial, the first from Saudi Arabia!
It confusing, though. I don't think it's actually a trial, even though it's registered as such at ClinicalTrials. It seems to be more of a round-up of recent research.
The study will look at:
Convalescent plasma transfusion
Hydroxychloroquine
DAS181
Ivermectin
Interferon Beta-1A
Somehow it will involve 200 patients in a observational cohort restrospective study.
Start date: 2020-07-25 Primary completion: 2020-08-15 Study completion: 2020-09-20
#Brief Summary:
On 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide. There are constant efforts by Health care workers to seek information regarding the Interventional and Observational studies which can help in decision making regarding effective handling of COVID-19 infected patients. It is also important to track on the happenings in various frontiers of COVID-19 Research in view of historical interest and clinical relevance. This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research. This study aims to get a birds eye view of ongoing COVID-19 Research scenario worldwide. This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.
I never heard of DAS181. There are 5 trials looking at DAS181 vs COVID-19. It's a US drug that's been fast-tracked by the FDA.
DAS181 is a recombinant sialidase protein that cleaves sialic acid located on the surface of epithelial cells lining the human respiratory tract. Many different viruses use sialic acid as a receptor for infecting the epithelial cells, and treatment with DAS181 can therefore block virus entry and prevent viral infection and spread. The drug has demonstrated anti-viral activity against multiple sialic acid-dependent viruses, which makes it uniquely suitable as a broad-spectrum treatment for many different respiratory viral infections. DAS181 is delivered in a nebulized formulation using Aerogen® Solo aerosol drug delivery technology.
permalink